Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma 3Endometrial Neoplasms 3Ovarian Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Glioma 1Gallbladder Neoplasms 1Estrogen Receptor Positive 1Esophageal Neoplasms 1

Interventions

Dexamethasone 337Bortezomib 187Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × copanlisib × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05490771 2026-05-05

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06400238 2026-05-05

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡